CO54 Dupilumab vs Placebo Improves Symptoms, Asthma Control, and Asthma-Related Quality of Life in Patients With Oral Corticosteroid-Dependent Severe Asthma Through 48 Weeks of Follow up
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.133
https://www.valueinhealthjournal.com/article/S1098-3015(22)02337-3/fulltext
Title :
CO54 Dupilumab vs Placebo Improves Symptoms, Asthma Control, and Asthma-Related Quality of Life in Patients With Oral Corticosteroid-Dependent Severe Asthma Through 48 Weeks of Follow up
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02337-3&doi=10.1016/j.jval.2022.09.133
First page :
Section Title :
Open access? :
No
Section Order :
10878